Skip to main content
Premium Trial:

Request an Annual Quote

Bioscience Investment Fund Gets Manager, $5M Commitment

Premium

RESEARCH TRIANGLE PARK, NC--The North Carolina Biotechnology Center here selected the Durham firm Eno River Capital to set up and manage the center's new Bioscience Investment Fund. The center also obtained a commitment from Charlotte-based NationsBank to invest up to $5 million in the fund, which will invest in new biotechnology and bioscience companies in the state.

The biotechnology center conceived of the fund last year to stimulate the creation and growth of new biotechnology and bioscience companies in North Carolina. The state's General Assembly appropriated $7.5 million for the fund in 1997, and the center is working to raise an additional $22.5 million from the state and from private investors.

Investments by the fund in North Carolina companies, expected to start being placed by early fall, will range from $500,000 to $2 million per company, according to Tom Laundon, vice-president of business and technology development at the center.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.